Form 144: Neuronetics to Offer 381,640 Shares via Morgan Stanley

Rhea-AI Filing Summary

Neuronetics, Inc. (Form 144) filed a notice proposing the sale of 381,640 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 08/08/2025 and an aggregate market value of $1,419,700.80 against 66,124,820 shares outstanding. The shares to be sold were acquired from the issuer in a merger/acquisition on 12/10/2024.

The filing shows the purchase was paid in cash on 12/10/2024, reports no securities sold in the past three months, and includes the required signer representation that the seller is not aware of undisclosed material adverse information about the issuer. The notice identifies the executing broker and the exchange but provides no further financial results or forward guidance.

Positive

• Execution through a registered broker (Morgan Stanley Smith Barney LLC) is disclosed, supporting an orderly market sale.
• Full cash payment for the acquired securities on 12/10/2024 is stated, clarifying consideration.
• No securities sold in the past three months is reported, limiting immediate concerns about recent insider sales.

Negative

• None.

Insights

Financial Analyst

TL;DR Routine Form 144 disclosing a modest proposed sale of 381,640 shares; limited immediate market impact given disclosure details.

The filing presents a straightforward proposed sale executed through a broker with a stated aggregate value of $1,419,700.80. The securities were acquired in a merger/acquisition on 12/10/2024 and paid in cash the same day, suggesting the position arose from corporate transaction activity rather than open-market accumulation. The filer reports no sales in the past three months, which reduces concerns about immediate prior dilution. Absent additional company financials or insider context, this notice is informational and does not itself change the company’s financial picture.

Corporate Governance Expert

TL;DR Disclosure aligns with Rule 144 requirements; sale is broker-facilitated and tied to a recent merger/acquisition.

The form identifies the broker (Morgan Stanley Smith Barney LLC) and exchange (NASDAQ), and documents the acquisition source as the issuer via a merger on 12/10/2024. The filer affirms no undisclosed material adverse information and indicates no recent sales, meeting standard attestation language. This is a compliance-focused disclosure rather than a corporate governance event that alters board or management composition.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	381640	1419700.80	66124820	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/10/2024	Merger/Acquisition	Issuer			381640	12/10/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Neuronetics (STIM) Form 144 propose to sell?

The filing proposes the sale of 381,640 shares of Common stock with an aggregate market value of $1,419,700.80.

When was the proposed sale for STIM scheduled to occur?

The approximate date of sale listed in the notice is 08/08/2025.

How and when were the securities being sold acquired?

The shares were acquired from the issuer in a Merger/Acquisition on 12/10/2024 and paid for in cash on the same date.

Which broker and exchange are named in the Form 144 for STIM?

The broker is Morgan Stanley Smith Barney LLC and the securities are to be sold on NASDAQ.

Has the filer sold any Neuronetics securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.